Mineralys Therapeutics stock consolidates near $24.55 as weekly rebound slows amid ongoing technical pressure

Traders Union
All News
Companies
Mineralys Therapeutics up 1.53% today

Highlights

MLYS remains on a downward trajectory, continuing to trade below major resistance and long-term moving averages.
Bearish technical signals dominate, with weak momentum, oversold readings, and less than 20% probability of a near-term price increase.
Expected range for the coming week is $22.00 to $26.00, with downside risk if support at $24.10 fails.

Downside bias as multiple moving averages cap gains

MLYS is trading at $24.55, which remains below the MA-20 ($27.76), MA-50 ($27.98), and MA-200 ($32.85), highlighting persistent downward pressure in short-, medium-, and long-term perspectives. The Ichimoku Kijun sits at $27.18, which is above the current price and therefore acts as immediate resistance. Near-term support is found at the MA-5 ($24.10), with key support at the MA-10 EMA ($26.10), while immediate resistance is the Kijun ($27.18) and key resistance at the MA-50 ($27.98).

Oscillator divergence and intraday rebound amid weak momentum

On momentum, MACD on D1 remains in sell territory while ADX on D1 is neutral, reflecting subdued trend strength and an absence of clear directional momentum. RSI on D1 is weak at 38.20 and CCI signals oversold at –121.11, with Stoch RSI indicating a strong buy, showing oscillators are diverging and some oversold conditions may persist. BBP on D1 sits in oversold territory at –2.36, confirming sellers continue to dominate intraday. In today’s session, MLYS has rebounded 1.53% after opening lower, pointing to some stabilization. Over the past week, the stock rose $0.86 (2.32%) from a prev_week_close of $23.69, and is currently in the upper part of the weekly range with weekly volatility at a high 16.32%. This tone suggests a recovery from the week’s low and emerging consolidation near upper levels, though momentum does not support a decisive trend reversal yet.

Further downside risk with low probability for upside break

For the coming week, the projected range for MLYS is $22.00 to $26.00, keeping moves within about ±10% of the current price given recent volatility and a 52-week span between $12.59 and $47.65. The probability of a price increase remains very low (less than 20%) given that all W1 indicators (RSI-W1, MACD-W1, ADX-W1, MA-50-W1) signal bearishness or neutrality, making further downside more likely. The baseline scenario is for price stabilization between support and resistance, with ongoing sideways action. A bullish scenario would require a break above immediate resistance at $27.18, but W1 and D1 momentum both challenge this outcome. A bearish scenario becomes more probable if MLYS drops through near-term support around $24.10, exposing it to further declines toward the $22.00 level, which is still substantially above the 52-week low.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Mineralys Therapeutics faced sustained bearish momentum, with analysts highlighting persistent selling pressure and a challenging technical backdrop. In the current context, market participants should monitor for any shifts in trend or emerging catalysts, as a decisive move above key resistance could alter the prevailing scenario.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.